Published in Medical Letter on the CDC and FDA, November 1st, 2009
The corrected release reads: PROTALIX BIOTHERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE III CLINICAL TRIAL OF UPLYSO™ FOR THE TREATMENT OF GAUCHER DISEASE Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.